Physician profile
Rajinder Maan
NPI 1861747016
$842.92
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $253.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $269.99 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $125.36 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $86.88 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $64.01 | 2019-2020 | |
| Novo Nordisk INC | $49.88 | 2019-2020 | |
| Amarin Pharma, INC. | $45.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.77 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $33.50 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.84 | 2019-2020 | |
| Gilead Sciences, INC. | $21.30 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.50 | 2019 | |
| Boston Scientific Corporation | $16.52 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.32 | 2019 | |
| Pfizer INC. | $14.27 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajinder Maan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.